Dr. Heidi Overton’s Nomination for FDA Commissioner

Dr. Heidi Overton has been nominated by President Trump to serve as the next FDA commissioner. This nomination follows the resignation of Dr. Marty Makary in May, who served in the position for 13 months. Overton, a trained surgeon, currently holds the position of deputy assistant to the president for domestic policy at the White House.

Dr. Joshua Sharfstein, who was formerly the principal deputy commissioner at the FDA during the Obama administration, commented on the potential transition for Overton from the White House to the FDA. Sharfstein emphasized that the move could offer new insights, as working at the FDA introduces one to career scientists who specialize in assessing medication safety. He noted that leading the FDA might be one of the most challenging roles in government health, overseeing about 18,000 employees and regulating a wide array of products including food, drugs, medical devices, and more.

Sharfstein explained that successful FDA commissioners require both intelligence and resilience. They face various pressures, including political, business, and advocacy challenges.

Previously with the America First Policy Institute, Overton authored papers against gender-affirming care for minors and questioned the safety of telehealth-prescribed medication abortions. She has also expressed skepticism regarding some of the FDA’s decisions.

During an August 10 press event where President Trump signed an executive order about childhood vaccinations, Overton supported the initiative. The order, which stirred controversy by reiterating debunked links between vaccines and autism, advocated for single-dose vaccines for measles, mumps, and rubella, typically given together as an MMR or MMRV shot.

While she recommended the measles vaccine for all children, Overton encouraged parental discretion regarding vaccine scheduling. However, many public health experts, including Sharfstein, argue that separating these vaccines lacks scientific support and might increase costs and the risk of missed doses.

Overton’s nomination is pending Senate confirmation. Sen. Patty Murray from Washington has expressed her opposition to the nomination. Sen. Bill Cassidy from Louisiana, another medical professional, also voiced concerns online, though he did not disclose his voting intentions. NPR’s request to interview Overton remains unanswered by the White House.